Low-dose CT screening in relatives with a family history of lung cancer

Chi-Liang Wang,Kuo-Hsuan Hsu,Ya-Hsuan Chang,Chao-Chi Ho,Chun-Ju Chiang,Kun-Chieh Chen,Yun-Chung Cheung,Pei-Ching Huang,Yu-Ruei Chen,Chih-Yi Chen,Chung-Ping Hsu,Jiun-Yi Hsia,Hsuan-Yu Chen,Shi-Yi Yang,Yao-Jen Li,Tsung-Ying Yang,Jeng-Sen Tseng,Cheng-Yen Chuang,Chao A Hsiung,Yuh-Min Chen,Ming-Shyan Huang,Chong-Jen Yu,Kuan-Yu Chen,Wu-Chou Su,Jeremy J W Chen,Sung-Liang Yu,Chien-Jen Chen,Pan-Chyr Yang,Ying-Huang Tsai,Gee-Chen Chang,Chao A. Hsiung,Jeremy J.W. Chen
DOI: https://doi.org/10.1016/j.jtho.2023.06.018
IF: 20.121
2023-07-01
Journal of Thoracic Oncology
Abstract:INTRODUCTION: The role of a family history of lung cancer (LCFH) in screening using low-dose computed tomography (LDCT) has not been prospectively investigated with long-term follow-up.METHODS: A multicenter prospective study with up to three rounds of annual LDCT screening was conducted to determine the detection rate of lung cancer (LC) in asymptomatic first- or second-degree relatives of LCFH.RESULTS: From 2007 to 2011, there were 1102 participants enrolled, including 805 and 297 from simplex and multiplex families (MFs), respectively (54.2% women and 70.0% never-smokers). The last follow-up date was May 5, 2021. The overall LC detection rate was 4.5% (50 of 1102). The detection rate in MF was 9.4% (19 of 202) and 4.4% (4 of 91) in never-smokers and in those who smoked, respectively. The corresponding rates for simplex families were 3.7% (21 of 569) and 2.7% (6 of 223), respectively. Of these, 68.0% and 22.0% of cases with stage I and IV diseases, respectively. LC diagnoses within a 3-year interval from the initial screening tend to be younger, have a higher detection rate, and have stage I disease; thereafter, more stage III-IV disease and 66.7% (16 of 24) with negative or semipositive nodules in initial computed tomography scans. Within the 6-year interval, only maternal (modified rate ratio = 4.46, 95% confidence interval: 2.32-8.56) or maternal relative history of LC (modified rate ratio = 5.41, 95% confidence interval: 2.84-10.30) increased the risk of LC.CONCLUSIONS: LCFH is a risk factor for LC and is increased with MF history, among never-smokers, younger adults, and those with maternal relatives with LC. Randomized controlled trials are needed to confirm the mortality benefit of LDCT screening in those with LCFH.
oncology,respiratory system
What problem does this paper attempt to address?